Studies show that rapid eating is associated with reduced satiety hormone responses and increased risk of obesity and metabolic syndrome
the molecule may not be absorbed effectively in the digestive tract the dose may be too small to influence cellular physiology the compound may break down before reaching target tissues the body may rapidly eliminate it through the liver or kidneys Even when a compound is absorbed into the bloodstream, that does not necessarily mean it will influence cellular biology
Soon others will enter the market such as Amgens AMG 133 is in development, and ZYOG1 is an investigational oral GLP-1 receptor agonist developed by Zealand Pharma
[Google Scholar] Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjrge T, Borena W, Hggstrm C, Engeland A, Nagel G, Almquist M, Selmer R, Tretli S, Concin H, Hallmans G, Jonsson H, Stattin P, Ulmer H, 2013
& Vlatkovic, I
[A: 13:45, V: 14:13]